Suyash Prasad, M.B.B.S, F.F.P.M
2021
In 2021, Suyash Prasad, M.B.B.S, F.F.P.M earned a total compensation of $2.2M as Chief Medical Officer and Head of Research and Development at Taysha Gene Therapies, a 44% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $181,692 |
|---|---|
| Option Awards | $1,613,721 |
| Salary | $432,600 |
| Other | $3,051 |
| Total | $2,231,064 |
FFPM received $1.6M in option awards, accounting for 72% of the total pay in 2021.
FFPM also received $181.7K in non-equity incentive plan, $432.6K in salary and $3.1K in other compensation.
Rankings
In 2021, Suyash Prasad, M.B.B.S, F.F.P.M's compensation ranked 5,610th out of 12,415 executives tracked by ExecPay. In other words, FFPM earned more than 54.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,610 out of 12,415 | 55th |
Division Manufacturing | 2,376 out of 5,505 | 57th |
Major group Chemicals And Allied Products | 1,031 out of 2,375 | 57th |
Industry group Drugs | 920 out of 2,096 | 56th |
Industry Biological Products, Except Diagnostic Substances | 223 out of 449 | 50th |
Source: SEC filing on April 28, 2022.
FFPM's colleagues
We found two more compensation records of executives who worked with Suyash Prasad, M.B.B.S, F.F.P.M at Taysha Gene Therapies in 2021.